naa a22 4500 510763146 CHVBK 20180411083146.0 cr unu---uuuuu 180411e20130101xx s 000 0 eng 10.1007/s12094-012-0885-0 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0885-0 Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience [Elektronische Daten] [Guo-Chun Zhang, Ning Liao, Zi-Bai Guo, Xue-Ke Qian, Chong-Yang Ren, Meng Yao, Xue-Rui Li, Kun Wang, Jian Zu] Introduction: The timing of sentinel lymph node biopsy (SLNB) of breast cancer in the neoadjuvant setting is still controversial. We retrospectively analyzed a Chinese patient cohort with neoadjuvant chemotherapy (NAC) to evaluate the accuracy and axilla sparing potentials of different SLNB timings with methylene blue alone for lymphatic mapping. Materials and methods: Patients with NAC and axillary lymph node dissection (ALND) and either pre- or post-NAC SLNB were eligible. Clinicopathological characteristics, identification rate (IR), false-negative rate (FNR), accuracy, and positive-predictive value were calculated and compared between the pre- and post-NAC SLNB group using appropriate statistical methods. Axilla sparing potentials of different SLNB timings were evaluated and compared. Results: One hundred and fifteen eligible cases were included, and 58 had pre-NAC SLNB while the other 57 had post-NAC SLNB. Both groups were comparable in clinicopathological characteristics, neoadjuvant treatments and pathologic complete response rate. IR, FNR, and accuracy of SLNB, as pre-NAC versus post-NAC, were 100 versus 98.2% (P=0.496), 0 versus 8.0% (P=0.181), and 100 versus 96.4% (P=0.239), respectively. Post-NAC SLNB had significantly higher positive-predictive value for ALNs than pre-NAC SLNB (70.0 vs. 36.4%, P=0.014), suggesting as high as 63.6% of ALND performed in the pre-NAC group could have been avoided while only 30% of ALND in the post-NAC group were theoretically unnecessary. Conclusions: Both SLNB timings of breast cancer patients with NAC were feasible and accurate. Although pre-NAC SLNB tends to be better in accuracy, post-NAC SLNB is significantly superior in terms of axilla sparing. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Breast cancer nationallicence Neoadjuvant chemotherapy nationallicence Sentinel lymph node biopsy nationallicence Axilla sparing nationallicence Zhang Guo-Chun Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut Liao Ning Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut Guo Zi-Bai Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut Qian Xue-Ke Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut Ren Chong-Yang Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut Yao Meng Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut Li Xue-Rui Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut Wang Kun Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut Zu Jian Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 79-84 1699-048X 15:1<79 2013 15 12094 https://doi.org/10.1007/s12094-012-0885-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0885-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zhang Guo-Chun Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut NATIONALLICENCE 700 1- Liao Ning Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut NATIONALLICENCE 700 1- Guo Zi-Bai Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut NATIONALLICENCE 700 1- Qian Xue-Ke Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut NATIONALLICENCE 700 1- Ren Chong-Yang Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut NATIONALLICENCE 700 1- Yao Meng Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut NATIONALLICENCE 700 1- Li Xue-Rui Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut NATIONALLICENCE 700 1- Wang Kun Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut NATIONALLICENCE 700 1- Zu Jian Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 79-84 1699-048X 15:1<79 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer